June 23, 2016
(Manged Care Magazine) – The first patient has been vaccinated with an active tau vaccine, AADvac1 (Axon Neuroscience), in the phase 2 ADAMANT trial. AADvac1 was developed to be the first disease-modifying tau vaccine for patients with Alzheimer’s disease (AD) and other tauopathies. The ADAMANT trial is a 24-month, randomized, placebo-controlled, parallel-group, double-blind, multicenter study designed to assess the safety and efficacy of AADvac1 in patients with mild AD.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.